Prothena (PRTA) “announced a scientific presentation at Neuroscience 2025, hosted by the Society for Neuroscience in San Diego, CA. CYTOPE is a novel drug delivery modality enabling cytosolic delivery of macromolecules in the brain and periphery through an efficient endosomal escape mechanism that preserves membrane and vesicle integrity following systemic administration. This technology potentially allows for targeting of previously undruggable intracellular disease targets. To demonstrate this, we developed and investigated our TDP-43 CYTOPE program in multiple preclinical models.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Coramitug: Promising Phase 2 Results and Buy Rating for ATTR-CM Advancements
- Prothena highlights positive Phase 2 Coramitug data published in AHA journal
- Prothena price target raised to $30 from $20 at H.C. Wainwright
- Prothena Corporation’s Q3 2025 Financial and Clinical Updates
- Prothena reports Q3 EPS (68c), consensus (54c)